BioTuesdays

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program.

Radiopharmaceuticals that use modern medical isotopes like Lu-177 are much easier for patients to access, as they can be administered outside of hospitals without an overnight stay. Whenever POINT uses Lu-177 in a program, only n.c.a. Lu-177 is utilized.

The input material for creating n.c.a. Lu-177 is Yb-176, a stable isotope precursor that is irradiated in nuclear reactors, producing Lu-177 through neutron activation. Currently, the production of all n.c.a. Lu-177 depends on a complex and very limited global supply chain. 

Kinectrics is a service provider to the nuclear power and electricity industry.

Under the accord with Kinectrics, POINT is laying the groundwork to access large quantities of highly enriched Yb-176, creating the world’s first, stable North American supply of n.c.a. Lu-177, and establishing POINT as a provider of high-quality radiopharmaceuticals.

“Ensuring a secure, redundant and consistent isotope supply is a cornerstone of POINT’s radiopharmaceutical platform,” Dr. Joe McCann, CEO of POINT, said in a statement. 

“Our integrated Lu-177 isotope supply chain is a rarity in the industry, allowing us to advance our pipeline and positions us as a future leader in the commercial supply of these treatments,” he added. 

David Harris, CEO of Kinectrics, said creating a North American supply of Yb-176 is critical to safeguard the supply-chain for Lu-177.

“Kinectrics is uniquely positioned to apply our international capabilities in engineering, physics, and chemistry to develop state-of-the-art stable isotope enrichment technologies,” he added. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.